|
|
|
|
| Stem cells are the backbone of many allogeneic therapies and where they come from affects development and supply chain logistics, particularly cryopreservation. What temperatures are ideal to maintain product potency? How do you build a reliable cold chain? How do you work with existing infrastructure to allow for an “off-the-shelf” therapy? Don’t miss the next Cell & Gene Live digital event! Registration is free thanks to the support of Charter Medical and Bio-Techne. |
|
|
|
|
By Shalini Nagar, Research Nester | Biolistic particle delivery aims to insert genetic material or molecules into cells for various purposes like genetic engineering, gene therapy, and plant modification. From this, researchers can study gene function, modify traits, or develop new therapies. |
|
|
|
| FDA Steps Up Support For Advanced Manufacturing Technologies | White Paper | By Bikash Chatterjee, Pharmatech Associates - A USP Company | Examine the potential of the FDA and NIST's MOU to provide critical technical guidance that could standardize approaches for implementing AMTs, such as those used in continuous manufacturing. |
|
|
|
| In Focus: The C Of CDMO | Article | Comprehensive Cell Solutions, A Business Unit of NYBC Enterprises | Delve into the intricacies of a successful CDMO relationship and learn how a collaborative approach built on shared goals and open communication can maximize the potential of your cell therapy program. |
|
|
|
| Navigating The Allogeneic Commercialization Journey | Article | FUJIFILM Diosynth Biotechnologies | Review the pivotal moments, challenges, triumphs, and lessons learned that have shaped an evolution from facility construction to a fully operational, patient focused CDMO. |
|
|
|
|
|
| Connect With Cell & Gene: |
|
|
|
